AURORA, Ontario, Sept. 23 /PRNewswire/ -- Helix BioPharma announced today that Dr. Heman Chao, Vice President of Research at Helix BioPharma Corp., will be presenting L-DOS47 research findings at the National Research Council of Canada's (NRC) Eighth Annual General Meeting of the Genomics and Health Initiative, today in Saskatoon, Saskatchewan, Canada. The meeting includes Canadian researchers from across the NRC, government departments and private industry and covers diverse topics in genomics research.
Dr. Chao's presentation, titled "L-DOS47: Targeting the Tumor Microenvironment with an Immunoconjugate" will provide a summary of selected previously announced L-DOS47 research findings. "We are very pleased to have been invited to participate in this important scientific forum," said Dr. Chao. "It is an excellent opportunity to showcase our findings to Canada's research community as we continue to advance our L-DOS47 development program.
For additional information on the Genomics and Health Initiative conference, please visit: http://www.pbi.nrc.ca/ghi-agm.htm .
L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a
highly specific single domain antibody, to form a potential new targeted
drug product for the treatment of adenocarcinoma of the lung, the most
common form of cancer in the world today. L-DOS47 is thought to function by
leveraging a natural process in the body called the urea cycle, to produce
an anti-cancer effect. It is based upon a naturally occurring enzyme called
urease that essentially reverses the urea cycle by breaking down urea into
metabolites that include ammonia and hydroxyl ions. By doing so at the site
of cancerous tissues in the body, L-DOS47 is believed to modify the
microenvironmental conditions of lung cancer cells in a manner that leads
to their death. Among these theorized effects, L-DOS47 is believed to
|SOURCE Helix BioPharma|
Copyright©2008 PR Newswire.
All rights reserved